Skye Bioscience, Inc. (SKYE)

OTCMKTS: SKYE · Delayed Price · USD
15.62
+1.28 (8.93%)
Mar 28, 2024, 3:35 PM EDT - Market open
Market Cap 176.94M
Revenue (ttm) n/a
Net Income (ttm) -43.81M
Shares Out 971.55M
EPS (ttm) -10.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,154
Open 14.34
Previous Close 14.34
Day's Range 14.34 - 15.75
52-Week Range 1.44 - 19.41
Beta 1.71
Analysts Buy
Price Target 20.00 (+28.04%)
Earnings Date n/a

About SKYE

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, In... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 11
Stock Exchange OTCMKTS
Ticker Symbol SKYE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SKYE stock is "Buy" and the 12-month stock price forecast is $20.0.

Price Target
$20.0
(28.04% upside)
Analyst Consensus: Buy

News

Skye Bioscience Announces $40 Million Private Placement Equity Financing

Financing expected to fund strategic expansion of obesity clinical development and extend operating runway beyond 2026 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. ...

17 days ago - Newsfile Corp

Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercial...

24 days ago - GlobeNewsWire

Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company”), a clinical-stage biotechnology company focused on the discovery, development and commerciali...

4 weeks ago - GlobeNewsWire

Skye Bioscience to Present at Oppenheimer Investor Conference

San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused on the discovery, development and commercializ...

7 weeks ago - Newsfile Corp

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination wi...

2 months ago - Newsfile Corp

Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease

Phase 2 trial to assess impact of peripherally-acting CB1 inhibitor on weight loss and metabolic biomarkers related to co-morbid obesity and chronic kidney disease San Francisco, California--(Newsfile...

2 months ago - Newsfile Corp

Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab

Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11...

3 months ago - GlobeNewsWire

Skye Bioscience Responds to OTC Markets Promotional Policy

San Diego, California--(Newsfile Corp. - December 8, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid syst...

3 months ago - Newsfile Corp

Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endoca...

4 months ago - Newsfile Corp

Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing drugs targeting the endocannabinoid system, focusing on ...

4 months ago - GlobeNewsWire

Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit

San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system to address di...

4 months ago - Newsfile Corp

Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma

• SBI-100 OE is well tolerated, with low rate of hyperaemia (8.4%)• Reduced intraocular pressure (23% mean reduction) in healthy volunteers with higher baseline IOP (>17 mm Hg) San Diego, California--...

5 months ago - Newsfile Corp

CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Phase 1 clinical data to be released in conjunction with Investor Day This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc. San Diego, Califor...

5 months ago - Newsfile Corp

Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"

Phase 1 clinical data to be released in conjunction with Investor Day San Diego, California--(Newsfile Corp. - October 19, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pha...

5 months ago - Newsfile Corp

Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist Phase 1 study complete and data will be reported in October San Diego, California--(Newsfile Corp. - September 27, ...

6 months ago - Newsfile Corp

Skye Bioscience Announces Participation at Upcoming Investor Conferences

San Diego, California--(Newsfile Corp. - September 22, 2023) - Skye Bioscience, Inc. (OTCQB: SKYED) ("Skye" or the "Company"), a pharmaceutical company developing proprietary medicines that modulate t...

6 months ago - Newsfile Corp

Skye Bioscience Reverse Stock Split to Be Effective on September 8th

San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid ...

7 months ago - Newsfile Corp

Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference

San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid ...

7 months ago - Newsfile Corp

Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody

Acquisition of Bird Rock Bio builds Skye's position as a leading endocannabinoid system-focused pharmaceutical company New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a fir...

7 months ago - Newsfile Corp

Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat g...

8 months ago - Newsfile Corp

Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion

Skye preparing to start Phase 2a glaucoma clinical trial in Q3 San Diego, California--(Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...

9 months ago - Newsfile Corp

Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial

San Diego, California--(Newsfile Corp. - July 6, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivat...

9 months ago - Newsfile Corp

Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion

Skye completes dosing of final cohort of healthy volunteers in study of first-and-only-in-class proprietary cannabinoid derivative San Diego, California--(Newsfile Corp. - June 12, 2023) - Skye Biosci...

10 months ago - Newsfile Corp

Skye Bioscience to Present at LD Micro Invitational XIII

San Diego, California--(Newsfile Corp. - June 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivat...

10 months ago - Newsfile Corp

Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

Skye plans to complete enrollment of Phase 1 study in June San Diego, California--(Newsfile Corp. - June 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical comp...

10 months ago - Newsfile Corp